BeiGene Announces Board Changes and Officer Compensation Details
Ticker: BEIGF · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $620,000, $5,000,000, $930,000, $559,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation
Related Tickers: BGNE
TL;DR
BeiGene's board got a new director, Dr. Xiaodong Wang, and Dr. Robert T. Li stepped down. Officer pay details also filed.
AI Summary
On July 17, 2024, BeiGene, Ltd. announced changes to its Board of Directors, including the appointment of Dr. Xiaodong Wang as a Class II Director and the resignation of Dr. Robert T. Li. The company also disclosed compensatory arrangements for certain officers, though specific details were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in strategic direction or governance, while details on officer compensation are important for understanding executive incentives and company spending.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board and officer changes and compensatory arrangements, which are standard disclosures and do not inherently indicate significant new risks.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Dr. Xiaodong Wang (person) — Appointed Class II Director
- Dr. Robert T. Li (person) — Resigned Director
- July 17, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new Class II Director at BeiGene, Ltd.?
Dr. Xiaodong Wang has been appointed as a Class II Director.
Who has resigned from BeiGene, Ltd.'s Board of Directors?
Dr. Robert T. Li has resigned from the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 17, 2024.
What specific compensatory arrangements for officers were disclosed?
The filing indicates disclosure of compensatory arrangements of certain officers, but the specific details are not provided within this document excerpt.
What is BeiGene, Ltd.'s Standard Industrial Classification (SIC) code?
BeiGene, Ltd.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 1,568 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2024-07-18 06:40:34
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
- $620,000 — senberg will receive a base salary of US$620,000 and is eligible for an annual bonus wit
- $5,000,000 — quity awards with an initial value of US$5,000,000 on the date of grant, consisting of 1/3
- $930,000 — . Wang will receive a cash payment of US$930,000 (reflecting 18 months base salary), and
- $559,500 — eflecting 18 months base salary), and US$559,500 (reflecting 18 months of the target bon
Filing Documents
- bgne-20240717.htm (8-K) — 44KB
- a20240718formxcfochangexex.htm (EX-99.1) — 15KB
- 0001651308-24-000086.txt ( ) — 190KB
- bgne-20240717.xsd (EX-101.SCH) — 2KB
- bgne-20240717_lab.xml (EX-101.LAB) — 22KB
- bgne-20240717_pre.xml (EX-101.PRE) — 13KB
- bgne-20240717_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On July 18, 2024, the Company issued a press release relating to the matters described above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release titled "BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer" issued by BeiGene, Ltd. on July 18, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 99.1 Press release titled "BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer" issued by BeiGene, Ltd. on July 18, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: July 18, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel